Aortic stenosis (AS) and atherosclerosis are progressive cardiovascular conditions that frequently coexist and share multiple clinical and molecular features. Medical therapies have shown effectiveness in preventing and treating atherosclerosis and its consequences. For AS, effective pharmacological therapies remain limited. Understanding the shared risk factors and mechanisms between the two conditions may provide opportunities for therapeutic repositioning in AS. We performed a narrative review focusing on studies published from 2005 to 2025. Inclusion criteria encompassed clinical trials, experimental models, and molecular studies addressing overlapping risk factors, pathological pathways, and treatment approaches for AS and atherosclerosis. AS and atherosclerosis share key risk factors, including age, hypertension, hyperlipidemia, and diabetes. Molecular mechanisms, such as chronic inflammation, endothelial dysfunction, oxidative stress, lipid accumulation, and calcific remodeling, are common to both. Pathways involving the renin-angiotensin system, Notch signaling, and osteogenic mediators contribute to disease progression. Several drug classes, notably proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, lipoprotein(a) (Lp(a)) lowering therapies, anti-inflammatory agents, and immunomodulators, show potential for repositioning in AS management. The substantial overlap in risk factors and molecular mechanisms between AS and atherosclerosis supports a rationale for therapeutic repositioning. Targeting shared pathways could lead to innovative strategies for slowing AS progression and improving patient outcomes.
Background/Objectives: Risk stratification and prognostic prediction are embedded in revascularization practice for acute coronary syndromes, but the longitudinal evolution and scientific architecture of this literature remain poorly characterized. We mapped growth, contributors, conceptual structure, and named instruments. Methods: English-language articles and reviews indexed in the Web of Science Core Collection from 1975 to 2025 were retrieved with a three-block Topic search (n = 10,390; 9608 articles, 782 reviews). Bibliometric performance, collaboration, source impact, keyword co-occurrence (validated thesaurus), named instrument and clinical setting terms, and metadata completeness were analyzed with VOSviewer, Bibliometrix/Biblioshiny, and Python. Annual output was modeled by changepoint detection with bootstrap localization. Results: Annual output rose from 8 records in 1988 to 843 in 2025; the principal transition was a slowdown in proportional growth around 2009, from approximately 16.5% to 6.9% annually, reproduced on the 1991–2025 series. The United States led output, citations, and collaboration strength; China ranked second in volume, with the youngest output among the leading countries (median year 2022) and year-normalized citation impact of 0.78 versus 1.43 for the United States (corpus average 1.0). A 92-keyword network formed five clusters centered on percutaneous coronary intervention (PCI). SYNTAX, TIMI, and GRACE were the most frequently named scores, and machine learning terminology grew fastest (53 records in 2025). Records naming ST-segment elevation myocardial infarction alone (33.9%) outnumbered those naming non-ST-elevation presentations alone (13.7%), and 75.7% mentioned PCI without bypass surgery. Conclusions: These patterns suggest that prognostic assessment has developed primarily within revascularization practice rather than as an independent methodological field; machine learning and high bleeding risk terminology are emerging below the keyword map threshold.